CEL-SCI Says Serbia Approves Enrollment Of Subjects In Multikine Phase III Trial

(RTTNews) - CEL-SCI Corp. (CVM), a late-stage oncology company, Thursday said it has received approval from the Medicines and Medical Device Agency of Serbia to begin enrollment of subjects in its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine or Leukocyte Interleukin, Injection.

Multikine is the first immunotherapeutic agent being developed as a potential first-line treatment for advanced primary head and neck cancer.

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant, 10% improvement in overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care compared to subjects who are treated with SOC only.

CEL-SCI's Multikine investigational immunotherapy is intended to create an anti-tumor immune response to reduce local/regional tumor recurrence and thereby increase the survival rate of these patients.

According to the company, Serbia is the 11th country from which approval to participate in the world's largest Phase III trial for the treatment of head and neck cancer has been obtained.

CEL-SCI CEO Geert Kersten stated, "We are pleased to advance our Phase III trial, as Serbia becomes the latest country to participate in this important immunotherapy trial."